Metoprolol CR/ZOK (controlled release, zero order kinetics) is a new formulation of an extensively used β1‐selective, β‐adrenoceptor blocking drug, (β1,‐blocker), designed to provide continuous, even, plasma concentrations in the therapeutic range. It should, therefore, provide an effective well‐tolerated treatment for hypertension and angina pectoris and for use in secondary prevention following a myocardial infarct. The purpose of this review is to consider the need for such a formulation, to describe its pharmaceutical development, review its pharmacology and assess its efficacy and tolerability compared with other available agents.

Metoprolol CR/ZOK is a new formulation of a well-tolerated beta-blocker for treating hypertension, angina pectoris, and secondary prevention after a myocardial infarct.

Paper

METOPROLOL—CONTROLLED RELEASE, ZERO ORDER KINETICS

References

Citations